Strategic partnerships FOXO has announced a strategic partnership with Longevity Financial Partners to commercialize epigenetics technology, indicating potential pilot programs or co-sell opportunities in aging-focused insurance and financial services channels.

CFO leadership Recent appointment of a new Chief Financial Officer suggests a focus on governance, budgeting, and scalable financial operations, signaling readiness for growth initiatives and more formalized enterprise sales cycles.

Acquisition activity Active acquisition plans including Vector Biosource and a Florida assisted living facility imply expansion into healthcare data assets and senior living markets, opening opportunities for integrated underwriting, risk analytics, and care-environment partnerships.

Epigenetics platform FO XO’s emphasis on epigenetic biomarkers and ML/AI driven health insights positions the company to target disability and longevity risk segments, enabling collaborations with insurers, healthcare providers, and tech-enabled wellness programs.

Funding strength With substantial funding and a revenue range in the mid-market, FOXO may pursue enterprise deals, co-development arrangements, or licensing of its underwriting and engagement platform to scale with mid-to-large insurers and financial services partners.